ATEM Capital is a New York-based venture capital firm investing in life sciences and biotechnology companies, with emphasis on innovations addressing unmet clinical need, strong IP protection and strategic relevance. It backs early-stage and later-stage opportunities across biotechnology, pharmaceuticals and HealthTech, with investment activity in the United States, Europe and France. Portfolio examples include Amolyt Pharma, Triumvira Immunologics, Arpeggio Biosciences, Atea Pharmaceuticals and Syndax Pharmaceuticals.